证券代码：300430 证券简称：诚益通 公告编号：2026-001 北京诚益通控制技术集团股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 北京诚益通控制技术集团股份有限公司（以下简称 "公司"）（证券代码： 300430；证券简称：诚益通）股票于 2026 年 1 月 5 日、2026 年 1 月 6 日连续二 个交易日收盘价格涨幅偏离值累计达到 40.30%，根据《深圳证券交易所股票交 易规则》的有关规定，属于股票交易异常波动的情形。 二、公司关注并核实情况说明 三、是否存在应披露而未披露信息的说明 公司董事会确认，除在指定媒体已公开披露的信息外，公司目前没有任何根 据《深圳证券交易所创业板股票上市规则》等有关规定应予以披露而未披露的事 项；董事会也未获悉公司有根据《深圳证券交易所创业板股票上市规则》的有关 规定应予以披露而未披露的、对公司股票及其衍生品种交易价格产生较大影响的 信息；公司前期披露的信息不存在需要更正、补充之处。 4、公司、控股股东和实际控制人不存在关于本公司的应披露 ...

诚益通今日涨停，全天换手率34.79%，成交额24.05亿元，振幅12.94%。龙虎榜数据显示，机构净卖出 1586.71万元，深股通净买入1916.46万元，营业部席位合计净买入4910.61万元。 深交所公开信息显示，当日该股因日收盘价涨幅达20.00%上榜，机构专用席位净卖出1586.71万元，深 股通净买入1916.46万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交4.43亿元，其中，买入成交额为2.48亿 元，卖出成交额为1.95亿元，合计净买入5240.36万元。 具体来看，今日上榜的营业部中，共有3家机构专用席位现身，即买五、卖三、卖五，合计买入金额 4217.66万元，卖出金额5804.37万元，合计净卖出1586.71万元，深股通为第二大买入营业部及第二大卖 出营业部，买入金额为5496.82万元，卖出金额为3580.36万元，合计净买入1916.46万元。 资金流向方面，今日该股主力资金净流入1.89亿元，其中，特大单净流入3.03亿元，大单资金净流出 1.14亿元。近5日主力资金净流入4.45亿元。（数据宝） 诚益通1月6日交易公开信息 | 买/ 卖 | 会员营业部名称 ...

今日涨跌幅居前的概念板块 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 002195 | 岩山科 技 | 10.00 | 1.28 | 49272.01 | 80.37 | | 300430 | 诚益通 | 19.99 | 34.79 | 18886.96 | 7.85 | | 301293 | 三博脑 科 | 20.01 | 2.21 | 14128.55 | 46.71 | | 002173 | 创新医 疗 | 10.02 | 1.26 | 11284.03 | 82.52 | | 000516 | 国际医 学 | 9.96 | 2.16 | 9211.37 | 37.34 | | 603716 | 塞力医 疗 | 10.00 | 3.53 | 7079.50 | 38.34 | | 300753 | 爱朋医 | 20.00 | 17.90 | 7057.72 | 11.41 | | --- | --- | --- ...

证券之星消息，1月6日通用设备板块较上一交易日上涨0.87%，诚益通领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。通用设备板块个股涨跌见下表： 从资金流向上来看，当日通用设备板块主力资金净流出21.83亿元，游资资金净流出4789.59万元，散户资 金净流入22.31亿元。通用设备板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002342 | 巨力索具 | 3.15 Z | 13.66% | -1.21亿 | -5.23% | -1.95 Z | -8.43% | | 600783 | 鲁信创投 | 2.00亿 | 10.55% | -1.12 Z | -5.90% | -8812.56万 | -4.65% | | 300430 | 诚益通 | 1.79亿 | 7.44% | -1.66 Z | -6.91% | -1276.06万 ...

Market Overview - The A-share market continued to rise, with the Shanghai Composite Index achieving a 13-day winning streak, closing at 4083 points, up 1.5% [1] - The total market turnover reached 2.83 trillion yuan, an increase of 265 billion yuan from the previous trading day, with over 4100 stocks rising and nearly 150 stocks hitting the daily limit [1] Sector Performance - The brain-computer interface sector saw significant gains, with stocks like Sanbo Brain Science and Weisi Medical hitting the daily limit [2][4] - The titanium dioxide sector also experienced a collective price increase, with companies like Anning Shares and Vanadium Titanium Shares reaching the daily limit [2][6] - Brokerage stocks rose, with Huashan Securities and Hualin Securities hitting the daily limit [2][8] - Other sectors that performed well included industrial metals, silicon energy, electronic paper, and chemical raw materials [2] Brain-Computer Interface Sector - The brain-computer interface sector was particularly strong, with stocks like Beiyikang and Weisi Medical seeing gains of around 20% [5] - Elon Musk announced that Neuralink, his brain-computer interface company, plans to start large-scale production in 2026, which has positively impacted the sector [4] Titanium Dioxide Sector - The titanium dioxide industry recently issued a price increase notice to reverse previous low pricing and low profitability, indicating a potential recovery in industry profits [6] - Major domestic titanium dioxide companies are accelerating the layout of chloride process capacity, with Tianyuan Co. announcing a 1.48 billion yuan investment in a new project [6] Brokerage Sector - The brokerage sector is benefiting from high market activity, with the Shanghai Composite Index recording a 12-day winning streak and turnover exceeding 1 trillion yuan [8] - Analysts suggest that the improved policy environment and influx of funds will enhance the investment value of the brokerage sector, supporting growth in wealth management and self-operated business revenues [8] Industrial Metals Sector - The industrial metals sector is experiencing price increases driven by both financial and commodity attributes, with low global copper and aluminum inventories and expected demand growth from the recovering Chinese economy [12] - Stocks like Liyuan Shares and Chang Aluminum have seen significant gains, with some hitting the daily limit [13] Electronic Paper Sector - The electronic paper sector is also on the rise, with Su Dawei and other companies achieving substantial gains following a collaboration announcement with Shanghai Yudi Optoelectronics [14][15]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The brain-computer interface (BCI) technology is undergoing a period of accelerated transformation, with various technical paths available, including invasive, semi-invasive, and non-invasive methods, each with its own advantages in signal quality, safety, and operational difficulty [5][19] - The Chinese brain-computer interface market is projected to grow significantly, with the market size reaching approximately 1.73 billion yuan in 2023, accounting for 12.5% of the global market [6] - The industry is supported by a three-pronged policy approach focusing on planning, payment, and standards, which is expected to facilitate rapid development [6][33] Summary by Sections 1. Brain-Computer Interface Overview - BCI is a multidisciplinary technology that integrates neuroscience, computer science, and engineering to enable communication between the brain and external devices [17] - The technology operates through a closed-loop system involving signal input, processing, device control, and feedback [17] 2. Policy Support for BCI Development - The Chinese government has issued several policies to support the BCI industry, including the "Implementation Opinions on Promoting the Innovation and Development of the Brain-Computer Interface Industry" which outlines goals for 2027 and 2030 [6][43] - The policies aim to establish a robust industrial ecosystem, enhance innovation capabilities, and promote clinical applications of BCI technologies [43][44] 3. Technological Advancements and Applications - Core technological breakthroughs are occurring in the upstream segment of the BCI industry, particularly in hardware such as electrodes and chips [7] - The medical application of BCI is predominant, with 56% of the market share in 2023, focusing on various therapeutic areas including cognitive disorders and movement disabilities [7][9] - Companies like Lepu Medical and Aipeng Medical are actively involved in developing deep brain stimulation (DBS) technologies, with some preparing for IPOs [7][8] 4. Investment Recommendations - The report suggests focusing on both invasive and non-invasive BCI products, with specific companies identified as beneficiaries based on their clinical trial progress and commercialization potential [8] - Notable companies include Aipeng Medical and Lepu Medical for invasive products, and Xiangyu Medical and Innovation Medical for non-invasive products [8]

Core Insights - The announcement by Elon Musk regarding Neuralink's mass production of brain-machine interface (BMI) devices has significantly boosted market confidence in the commercialization of this technology, leading to a surge in related A-share stocks on the first trading day of 2026 [2][3][10] Group 1: Market Reaction - On January 5, 2026, domestic BMI concept stocks collectively opened high, with companies like Beikang rising over 29.98% and several others hitting the daily limit of 20% [1] - The market's positive response reflects high expectations for the commercial prospects of brain-machine interfaces following Musk's announcements [2][3] Group 2: Neuralink's Developments - Neuralink has completed seven rounds of financing, raising over $1.3 billion, which is significant compared to the projected $2.9 billion global market size for BMIs in 2025 [3][4] - The company has achieved several milestones, including FDA approval for human clinical trials and the first human implantation of a BMI, marking its leadership in the field [3][4] Group 3: Clinical Advancements in China - 2025 was termed the "Year of Chinese Brain-Machine Interfaces," with numerous clinical breakthroughs in restoring motor and speech abilities for high-level paraplegics, visual reconstruction, and treatment of mental disorders [7][8][10] - Key clinical trials have been conducted by various institutions, demonstrating significant advancements in BMI technology and its applications [9] Group 4: Regulatory and Market Developments - The introduction of policies such as the inclusion of BMIs in medical insurance and the establishment of regulatory frameworks for BMI medical devices indicate a move towards commercialization [10] - In 2025, the Chinese BMI sector saw 24 financing rounds, a 30% increase year-on-year, signaling growing investor interest and confidence in the market [10] Group 5: Competitive Landscape - Despite the surge in stock prices, there are currently no pure-play BMI companies listed in China, with many firms still in the process of developing their products and seeking IPO opportunities [11][12] - Companies like Qiangnao Technology and Bori Kang are actively pursuing IPOs, indicating a competitive race to become the first publicly listed BMI company in China [12][13] Group 6: Future Outlook - The industry is expected to enter a commercialization phase in 2026, with a competitive landscape emerging as various companies aim to establish themselves in the market [14]

Core Viewpoint - The brain-computer interface (BCI) industry is experiencing rapid growth, driven by advancements in technology and supportive government policies, with significant developments expected by 2026 when large-scale production is set to begin [2][3]. Industry Developments - Neuralink plans to start mass production of BCI devices in 2026, utilizing nearly fully automated surgical processes [2]. - The BCI index in the A-share market rose by 9.37%, with over 20 stocks, including companies like Botao Bio and Sanbo Brain Science, hitting the daily limit [2]. - The National Healthcare Security Administration (NHSA) has issued guidelines for BCI rehabilitation charges, which has accelerated the industry's growth [2]. Policy Support - The 14th Five-Year Plan identifies BCI as one of six key future industries, with specific pricing projects established for both invasive and non-invasive BCI technologies [3]. - New regulations from the NHSA in September 2025 will facilitate the coding of innovative medical products, further promoting BCI clinical applications [3]. Technological Breakthroughs - China has made significant strides in invasive BCI technology, becoming the second country globally to enter clinical trials for invasive BCI systems [4]. - The "North Brain No. 1" GCP multi-center clinical trial, set to launch in October 2025, will be the first to implement a high-throughput, wireless, semi-invasive BCI system with over 100 channels [4]. Competitive Landscape - The BCI industry in China is competitive, with the potential to lead globally, as companies focus on serving downstream clients, including hospitals and patients [5]. - The BCI industry has established a complete supply chain, covering upstream materials and chips, midstream signal processing, and downstream applications in healthcare and consumer products [6]. Regulatory Focus - BCI products, especially invasive types, are classified as high-risk medical devices, necessitating strict regulatory oversight [8]. - Companies like Xiangyu Medical and Aipeng Medical are actively pursuing product registrations for various BCI applications, including rehabilitation and monitoring systems [8][9].

Market Overview - The Shanghai Composite Index closed at 4018.63 points, above the five-day moving average, with an increase of 1.25% [1] - The total trading volume of A-shares reached 24,812.35 billion yuan [1] Stocks Performance - A total of 1,955 A-shares have surpassed the five-day moving average, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - BeiYikang (18.85% deviation rate, 29.98% increase, latest price 44.96 yuan) [1] - WeiSi Medical (15.01% deviation rate, 20.00% increase, latest price 58.08 yuan) [1] - ChengYiTong (14.78% deviation rate, 19.98% increase, latest price 23.06 yuan) [1] Additional Notable Stocks - Other stocks with significant performance include: - GuanHao Biological (14.72% deviation rate, 20.00% increase, latest price 16.62 yuan) [1] - DiNaiKe (14.64% deviation rate, 20.00% increase, latest price 17.76 yuan) [1] - MeiHao Medical (14.46% deviation rate, 20.00% increase, latest price 28.86 yuan) [1] Trading Metrics - The trading turnover rates for the top performing stocks vary, with BeiYikang at 12.85% and WeiSi Medical at 7.20% [1] - The five-day moving average prices for these stocks range from 14.49 yuan to 282.35 yuan [1][2]

Core Viewpoint - The A-share market experienced a significant upward movement on the first trading day of 2026, with the Shanghai Composite Index rising over 1% and surpassing the 4000-point mark, driven by a surge in brain-computer interface (BCI) stocks [1] Group 1: Market Performance - The combined trading volume of the Shanghai and Shenzhen markets exceeded 1.6 trillion yuan, indicating a notable increase in market activity [1] - Several BCI-related stocks, including Sanbo Brain Science, Aipeng Medical, and others, reached the daily limit of a 20% increase [1][2] Group 2: Industry Insights - Elon Musk's recent comments regarding Neuralink's plans to mass-produce BCI devices by 2026 have sparked interest in the BCI sector, with expectations of significant advancements in technology and applications [3] - The global BCI market is projected to grow from $2.94 billion in 2025 to $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034 [3] - Recent research breakthroughs in medical applications such as movement recovery and communication have been reported, supported by favorable policies from the government, including separate pricing for new BCI technologies [4]